Envista Holdings Corp

NYSE:NVST

Medical - Equipment & Services

Healthcare
$23.75 +3.06%

+$0.76 today

Market cap
$3.81B
Beta
0.89
P/E (TTM)
62.0
EPS (TTM)
$0.41
52W Low $18.32High $30.42

Volume 1.92M

Average 2.94M

NVST Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Envista Holdings CorpNYSE: NVST

Research & Development · Q3 FY2026 · quarter ended Oct 2026

Research & development grows, but more slowly than its trailing trend

Q3 FY2026 research & development of $29.3M rose 3.5% year over year, behind the +12.2% change in trailing-twelve-month research & development. Sequentially, it fell 3.6% from the prior quarter. Over 3 fiscal years it compounded at +4.4% a year.

Context

  • Research & development amounted to 4.2% of revenue in FY2025, up 0.2 pp from a year earlier.
  • Research & development increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +3.5% toward the trailing-twelve-month pace of +12.2%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterOct 2026
$29.3M-3.6% QoQ
Last fiscal yearDec 2025
$114M+15.0% YoY
LTMOct 2026
$121.8M+12.2% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+3.5%——
1 year+15.0%——
3-year CAGR+4.4%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
114M USD
Year-over-year change
+15.0%
4-year CAGR
+3.2%

Research & Development vs competitors

How NVST compares with its peers on the latest reported figures

  • NVST's LTM Oct 2026 research & development of $121.8M is the 7th highest of the 11 companies compared; the peer median is $142.05M.
  • Its year-over-year change of +12.2% is the 5th highest of 8, against a peer median of +12.5%.
  • Research & development amounts to 4.2% of revenue for NVST, versus a peer median of 4.1%.
NVST Competitors Peer median
Research & Development for NVST and competitors
Company Period LTM YoY 3-year CAGR% of revenue
RAREUltragenyx Pharmaceutical Inc.LTM Mar 2026$770.95M +12.5%+2.0%115.2%
DYNDyne Therapeutics, Inc.LTM Jun 2026$445.71M +17.2%+40.8%—
APGEApogee Therapeutics, Inc.LTM Jun 2026$240.74M +15.7%+97.7%—
GRALGRAIL, Inc.LTM Jun 2026$190.99M -15.8%-15.9%115.6%
XRAYDENTSPLY SIRONA Inc.LTM Mar 2026$158M -0.6%-4.8%4.3%
SUPNSupernus Pharmaceuticals, Inc.LTM Jun 2026$126.09M +18.1%+12.5%15.2%
NVSTEnvista Holdings CorpLTM Oct 2026$121.8M +12.2%+4.4%4.2%
ICUIICU Medical, Inc.LTM Jun 2026$86.32M -2.5%-2.0%4.0%
CONConcentra Group Holdings Parent, Inc.LTM Sep 2026$0 ——0.0%
PRVAPrivia Health Group, Inc.LTM Jun 2026$0 ——0.0%
ALHCAlignment Healthcare, Inc.LTM Mar 2026$0 ——0.0%
Peer median (excluding NVST) $142.05M+12.5%+2.0%4.1%

Competitors are the stored peer set for NVST. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue2.51B2.57B2.57B2.51B2.72B
Cost of Revenue1.05B1.08B1.12B1.12B1.22B
Gross Profit1.46B1.49B1.45B1.39B1.5B
Gross Margin58.3%57.9%56.5%55.4%55.0%
Research & Development100.5M100.1M93.8M99.1M114M
Selling, General & Admin989.5M1.03B1.03B1.14B1.16B
Operating Expenses1.16B1.17B1.42B2.43B1.27B
Depreciation & Amortization151.9M162.1M162.6M123.1M116M
EBITDA524.3M522M490M279.5M329.8M
EBITDA Margin20.9%20.3%19.1%11.1%12.1%
Operating Income306.2M319.2M31.5M(1.04B)225.7M
Operating Margin12.2%12.4%1.2%-41.4%8.3%
Interest Income00000
Interest Expense54.1M38.4M63.4M46.4M36.6M
Other Income / Expenses(51.7M)(35.3M)(86.4M)(46.5M)(48.5M)
Income Before Tax254.5M283.9M(54.9M)(1.08B)177.2M
Pre-Tax Margin10.1%11.1%-2.1%-43.2%6.5%
Income Tax Expense(9M)45.9M45.3M33.9M130.2M
Net Income340.5M243.1M(100.2M)(1.12B)47M
Net Margin13.6%9.5%-3.9%-44.6%1.7%
EPS (Basic)1.631.46(0.60)(6.50)0.28
EPS (Diluted)1.481.34(0.60)(6.50)0.28
Weighted Avg Shares161.2M162.9M166.9M172.2M168M
Weighted Avg Shares (Diluted)177.6M177.6M166.9M172.2M169.2M

Envista Holdings Corp

NYSE:NVST

Intrinsic Alpha fair value

Locked

Current Price

$23.75

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.